FDA Accepted Wearable Sensor to Track Nerve Disease
A new digital measurement tool may help researchers better assess foot drop in patients with Charcot-Marie-Tooth disease.
Updated on Sept. 22, 2026 in Diabetes
Live Poll
Should medical regulators prioritize digital tracking tools over traditional clinical observation methods?
The FDA has accepted a letter of intent for a wearable sensor designed to objectively measure foot drop severity in patients with Charcot-Marie-Tooth disease type 1A. This marks the first inclusion of a digital health tool for a rare neurological condition into the FDA's ISTAND program.
Why it matters
Current clinical assessment tools often fail to capture the nuances of foot drop, leaving researchers without precise metrics to evaluate potential treatments. This sensor aims to provide high-resolution, objective data to better track progression and improvement in a condition that currently has no FDA-approved therapies.
The FDA accepted the letter of intent for a tool that uses wearable sensors to track gait parameters during a six-minute walk test. The tool is designed to capture high-resolution data on ankle motion and foot drop, which are currently assessed using less precise clinical scales.
The players
FDA
The federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, medical devices, and the nation's food supply.
The details
The tool uses movement sensors attached to the ankles and feet to capture precise biomechanical data as a patient walks. It specifically monitors ankle range of motion, the angle of foot drop, and mid-swing foot angle during a standardized six-minute walk test performed in clinical settings. By recording these continuous metrics, the device offers a more sensitive measurement of treatment-related changes than existing subjective or observation-based scales.
Timeline
The FDA launched the ISTAND program in 2020.
The FDA accepted the letter of intent on September 22, 2026.
Health Landscape
This acceptance marks the first inclusion of a digital health technology into the ISTAND program for a rare neurological condition. It reflects a broader shift toward integrating objective, sensor-derived data into the drug development process to fill gaps left by traditional clinical scales.
For individuals living with Charcot-Marie-Tooth disease type 1A, this development highlights the ongoing effort to improve how potential new therapies are evaluated. It is worth discussing the implications of digital monitoring for symptom management with your neurologist or care team.
The takeaway
The use of wearable sensors aims to provide a more accurate way to measure the physical impact of neurological diseases. Patients should continue to work closely with their physicians to monitor disease progression and discuss the latest developments in clinical measurement tools.
Further reading
Learn more about new diagnostic advancements and clinical trial updates in Diabetes.
More information
Review the official FDA announcement of sensor metric acceptance for further details on the qualification process.
Source note: This article includes information reported by U.S. Food and Drug Administration.
Live Poll
Should medical regulators prioritize digital tracking tools over traditional clinical observation methods?
